Refining post-blinatumomab risk stratification through ultrasensitive-based measurable residual disease assessment
Yazeed Samara1, Ibrahim Aldoss2
1Department of Stem Cell Transplant and Cellular Therapy, Kaiser Permenante, Los Angeles, CA.
Haematologica
|April 16, 2026
Abstract
None:
Not available.
